MediciNova (NASDAQ:MNOV – Get Free Report) and Xeris Biopharma (NASDAQ:XERS – Get Free Report) are both small-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their dividends, valuation, profitability, earnings, risk, institutional ownership and analyst recommendations.
Insider and Institutional Ownership
9.9% of MediciNova shares are owned by institutional investors. Comparatively, 42.7% of Xeris Biopharma shares are owned by institutional investors. 14.0% of MediciNova shares are owned by company insiders. Comparatively, 4.3% of Xeris Biopharma shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.
Valuation & Earnings
This table compares MediciNova and Xeris Biopharma”s top-line revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| MediciNova | $410,000.00 | 179.11 | -$12.00 million | ($0.21) | -7.10 |
| Xeris Biopharma | $335.41 million | 5.46 | $550,000.00 | ($0.11) | -91.39 |
Xeris Biopharma has higher revenue and earnings than MediciNova. Xeris Biopharma is trading at a lower price-to-earnings ratio than MediciNova, indicating that it is currently the more affordable of the two stocks.
Profitability
This table compares MediciNova and Xeris Biopharma’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| MediciNova | -1,168.70% | -26.51% | -24.39% |
| Xeris Biopharma | -5.12% | 338.21% | 3.50% |
Analyst Recommendations
This is a breakdown of current ratings and price targets for MediciNova and Xeris Biopharma, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| MediciNova | 1 | 1 | 4 | 1 | 2.71 |
| Xeris Biopharma | 1 | 2 | 4 | 0 | 2.43 |
MediciNova presently has a consensus price target of $7.75, suggesting a potential upside of 419.44%. Xeris Biopharma has a consensus price target of $13.20, suggesting a potential upside of 31.30%. Given MediciNova’s stronger consensus rating and higher possible upside, research analysts clearly believe MediciNova is more favorable than Xeris Biopharma.
Volatility & Risk
MediciNova has a beta of 0.61, suggesting that its share price is 39% less volatile than the S&P 500. Comparatively, Xeris Biopharma has a beta of 0.53, suggesting that its share price is 47% less volatile than the S&P 500.
About MediciNova
MediciNova, Inc., a biopharmaceutical company, focuses on developing novel and small molecule therapeutics for the treatment of serious diseases with unmet medical needs in the United States. It is developing MN-166 (ibudilast), an oral anti-inflammatory and neuroprotective agent for treating neurological and other disorders, such as primary and secondary progressive multiple sclerosis, amyotrophic lateral sclerosis, chemotherapy-induced peripheral neuropathy, degenerative cervical myelopathy, glioblastoma, and substance dependence and addiction, as well as prevention of acute respiratory distress syndrome, and long COVID. The company's product pipeline also includes MN-221 (bedoradrine), a selective beta-2-adrenergic receptor agonist for the treatment of acute exacerbations of asthma; MN-001 (tipelukast), an orally bioavailable small molecule compound to treat fibrotic and other diseases, including nonalcoholic fatty liver disease and idiopathic pulmonary fibrosis; and MN-029 (denibulin), a tubulin binding agent for treating solid tumor cancers. It has license agreements with Kyorin Pharmaceutical Co., Ltd; Angiogene Pharmaceuticals, Ltd.; and Meiji Seika Kaisha, Ltd. The company was incorporated in 2000 and is headquartered in La Jolla, California.
About Xeris Biopharma
Xeris Biopharma Holdings, Inc., a biopharmaceutical company, engages in developing and commercializing therapies in Illinois. The company offers Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia pediatric and adult patients; Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor proved for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome. It is also developing XP-8121, a once-weekly subcutaneous injection of levothyroxine that is in phase I clinical trial for the treatment of hypothyroidism; and non-aqueous XeriSol and XeriJect technologies for various therapies. The company was incorporated in 2005 and is headquartered in Chicago, Illinois.
Receive News & Ratings for MediciNova Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MediciNova and related companies with MarketBeat.com's FREE daily email newsletter.
